Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
2,030.00
-60.00 (-2.87%)
At close: Feb 6, 2026
Kangstem Biotech Revenue
Kangstem Biotech had revenue of 783.33M KRW in the quarter ending September 30, 2024, a decrease of -39.10%. This brings the company's revenue in the last twelve months to 12.77B, up 30.25% year-over-year. In the year 2023, Kangstem Biotech had annual revenue of 12.70B, down -22.06%.
Revenue (ttm)
12.77B
Revenue Growth
+30.25%
P/S Ratio
14.95
Revenue / Employee
131.70M
Employees
97
Market Cap
190.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 12.70B | -3.60B | -22.06% |
| Dec 31, 2022 | 16.30B | 3.90B | 31.41% |
| Dec 31, 2021 | 12.40B | 3.27B | 35.75% |
| Dec 31, 2020 | 9.14B | 3.13B | 52.18% |
| Dec 31, 2019 | 6.00B | -3.16B | -34.49% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 66.39B |
| Genome & Company | 25.95B |
| Prestige Biologics | 13.36B |
| QuadMedicine | 13.11B |
| TiumBio | 9.32B |
| Bio Solution | 8.27B |
| Vaxcell-Bio Therapeutics | 1.90B |
| NovMetaPharma | 1.30B |